RecruitingPhase 1NCT07138196

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

A Phase 1b, Open-label Dose Escalation Study to Evaluate the Safety, Pharmacodynamic, Pharmacokinetic and Preliminary Efficacy of Q702 in Subjects With Relapsed or Refractory Active Chronic Graft-versus-Host Disease (cGVHD)

Sponsor

Qurient Co., Ltd.

Enrollment

18 participants

Start Date

Dec 23, 2025

Study Type

INTERVENTIONAL

Conditions

Chronic Graft Versus Host Disease

Summary

Open-label, dose escalation study to evaluate safety, tolerability pharmacokinetic and pharmacodynamic activity, and efficacy of Adrixetinib (Q702) in subjects with relapsed or refractory active chronic graft-versus-host disease (cGVHD).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adrixetinib for people with chronic graft versus host disease. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAdrixetinib

Administered orally

Locations(8)

Hospital Clinic de Barcelona

Barcelona, Spain

Hospital General Universitario Gregorio Maranon

Madrid, Spain

Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda, Spain

Hospital Universitario Virgen de la Arrixaca

Murcia, Spain

Clinica Universidad de Navarra

Pamplona, Spain

Hospital Universitario Marques de Valdecilla

Santander, Spain

Hospital Universitario Virgen del Rocio

Seville, Spain

Instituto de Investigacion Sanitaria

Valencia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07138196

Related Trials

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

NCT059227616 locations

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686175 locations

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT059966275 locations

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

NCT0711603133 locations

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT0712407841 locations